PDFファイル - 医薬品医療機器総合機構
Contents
1. B BN BN 3 C 2 8 E BN BN 1 C 2 1 2 4 8C 8 BNI 5 BN I2. C a 6 1 3 IO 1 4 g HIV HBV HCV 0 SB 2 6 2 26 43 EL HE UGE EPS 3 34 1 539 0 a a a 4 698 C 8 89mg L BN IL y x
3. RE C 5 a Ee K i BN BN 1 UN C 13 850 C EAA GFR
4. lt 1g L 4 2 C 1 2 0 2 0 ae N UY J IRIS RE BN _ N 100 C C 4 BN II
5. BN BN mg L 5 9 0 8 C 7 4 gt OVLF 20 3 20 I
6. HE 1 3 15 000 g 10 2 N 15 000 x g 10 I CR 413 194 19 1 78 B596 0 68 1 1 1mg L
7. Passing Bablok N 8C A 1 0226x 0 5147 0 8911 100 18 B 1 25231x 0 1600 0 8326 499 NL Mae SKI 39 C BmLX3 5 A 0 5mLX3 GFR 500 363 7396 GFR p 0 170 829 8896 9496 819 p 0 001 C 9596 94 91 96
8. C C GFR A 1 0 5mL B0 5mL 50 a C 1 2 1mL 30 1 N 2 ie N UY J 1 0 5mL C 0 004mg L 100 30 40
9. 3 HIV HBV HCV RE HIV1 2 HBV HCV lt 1g L
10. JPOO0083 JPOO084 2 A UMA OQUBT95 Cystatin CS tary R tA 1 TS BN 3 B 1 6mL x 1 30 Cyatatin tC Supplamentary Reagent B 3 2 BC lt 1g L 4 BN 4 C 1 1mLX3 N Cystatin C Control Level 1 BN lt 1g L 5 C 2 1mLx3 5 N UY J BN N Cystatin Co Control LByel
11. 2 a 8 C 3 85 1 1596 3 C 2 3 CV 1096 4 0 27 9 4 mg L BN N UY J 0 05mg L N 20 0 006mg L 2 SD
12. 82 76 89 93 91 96 83 77 89 g596 81 77 85 88 83 94 f 95 92 97 64 57 71 6 C eGFR eGFR C eGFR mL min 1 73m mL min Grubb et al CAPA 8 KDIG0 2012 CDK EPI Grubb et al CAPA eGFR mL min 1 73Gm 5 130 x CysC 9 x age 7 7 KDIGD 2018 CDK EPI 5 CysC 0 8 eGFR mL min 1 73m5 133 x CysC 0 8 7799 x 0 996 CysC gt 0 8 eGFR mL min 1 73m5 133 x CysC 0 8 99 x 0 996 We 60 CA CHRONIC KI x 0 932 x 0 932 PA eGFR
13. ll BN Ci 2mLx3 Bf 0 92 2 N UY J OQLVO5 C N
14. 2 2 C 1 2 3 3 1 0 8 4mg L BN BN 1 5 20 aA 0 V0
15. DNEY DISEASE CKD NOMENCLATURE USED BY KDIGO CKD mLmim 1 73m RE CAPA 1 90 lt 084 8 60 89 0 85 1 19 3a 45 59 1 20 1 51 3b 30 44 1 52 2 09 4 15 29 2 10 3 42 5 lt 15 gt 3 43 CAPA GFR 4 690 9 ERM DA4717 FCC BB 1 6mLX 1 C 1 1mLX3 C 2 1mLX3 1 Simonsen O Grubb A Thysell H
16. SIEMENS OQNM 17 C a N C N Latex Cystatin C 1GO00AMY00144000 IFCC lt
17. The blood serum concentration of cystatin C gamma trace as a measure of the glomerular iltration rate Scand J Clin Lab Invest 1985 45 97 101 2 Handers E Erlandsen EJ Serum cystatin C as an endogenous marker of the renal function a review Clin Chem Lab Med 1999 37 389 95 Grubb A Diagnostic value of analysis of cystatin C and protein HC in biological fluids Clin Nephrol 1992 38 Suppl 1 S20 7 4 Coll E Botey A Alvarez L et al Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment Am J Kidney Dis 2000 36 9 34 anetti L Pardini E Genovesi M et al Thyroid function differently affects serum cystatin C and creatinine Concentrations J Endocrinol Invest 2005 28 346 9 6 KDIGO 2012 Clinical Practice Guideline for the Evaluation and anagement of Chronic Kidney Disease Kidney International Supplements 2013 3 1 S1 150 7 Mathew TH Australasian Creatinine Consensus WoOrking Group C hronic kidney disease and automatic reporting of estimated omerularfiltration rate a position statement Med J Aust 005 183 138 4 1 8 Levey AS Eckardt KU Tsukamoto Y et al Definition and classification of chronic kidney disease a position statement rom Kidney Disease Improving Global Outcomes KDIGO idney Int 2005 67 2089 100 Grubb et al Generation of a New Cystatin C Based Estimating Equation for Glomerular Filtration Rate by Use o
18. f 7 Assays Standardized to the International Calibrator Clin Chem 014 60 974 986 TEL 03 3493 8400 1 1 1 1 DL 113 066C OQNMG17C11 Rev 02
Download Pdf Manuals
Related Search